Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts

Deep brain stimulation for Parkinson’s disease: meta-analysis of results of randomized trials at varying lengths of follow-up

(2018) Alireza Mansouri et al.   JOURNAL OF NEUROSURGERY

Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study

(2017) Thomas E. Kimber et al.   INTERNAL MEDICINE JOURNAL

Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson’s disease therapy

(2017) Cristina Alcacer et al.   JOURNAL OF CLINICAL INVESTIGATION

Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients

(2017) Manuela Rosa et al.   MOVEMENT DISORDERS

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease

(2017) Susan H. Fox et al.   MOVEMENT DISORDERS

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias

(2017) Jennifer Stanic et al.   NEUROBIOLOGY OF DISEASE

Teaching Video Neuro Images : The underrecognized diphasic dyskinesia of Parkinson disease

(2017) Leo Verhagen Metman et al.   NEUROLOGY

Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research

(2017) Nadhir Litim et al.   NEUROPHARMACOLOGY

Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease

(2017) Mario Meloni et al.   PARKINSONISM & RELATED DISORDERS

Common Myths in the Use of Levodopa in Parkinson Disease

(2017) Alberto J. Espay et al.   JAMA Neurology

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

(2017) Rajesh Pahwa et al.   JAMA Neurology

A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA –Induced Dyskinesia and ∆FosB Expression

(2016) Michael Feyder et al.   BIOLOGICAL PSYCHIATRY

Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons

(2016) Polina Kosillo et al.   CEREBRAL CORTEX

L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

(2016) Luz M Suarez et al.   CEREBRAL CORTEX

Novel Levodopa Formulations for Parkinson’s Disease

(2016) Maria Eliza Freitas et al.   CNS DRUGS

Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease

(2016) Alessandra Nicoletti et al.   JOURNAL OF NEUROLOGY

Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease

(2016) Nicole C. Swann et al.   JOURNAL OF NEUROSCIENCE

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

(2016) Claudia Trenkwalder et al.   MOVEMENT DISORDERS

Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease

(2016) Damian M. Herz et al.   MOVEMENT DISORDERS

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

(2016) François Tison et al.   MOVEMENT DISORDERS

Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients

(2016) Angelo Antonini et al.   MOVEMENT DISORDERS

Hyperkinetic disorders and loss of synaptic downscaling

(2016) Paolo Calabresi et al.   NATURE NEUROSCIENCE

Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion

(2016) Francesco Bez et al.   NEUROBIOLOGY OF DISEASE

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias

(2016) Tanuja Bordia et al.   NEUROBIOLOGY OF DISEASE

Serotonin-to-dopamine transporter ratios in Parkinson disease

(2016) Andreas-Antonios Roussakis et al.   NEUROLOGY

Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease

(2015) Lisa F. Potts et al.   ANNALS OF NEUROLOGY

Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans

(2015) Damian M. Herz et al.   BRAIN

Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease

(2015) Flavia Niccolini et al.   BRAIN

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

(2015) Concepción García et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors

(2015) Martyn Wood et al.   BRITISH JOURNAL OF PHARMACOLOGY

NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat

(2015) H. Iderberg et al.   EXPERIMENTAL NEUROLOGY

Adaptive deep brain stimulation in a freely moving parkinsonian patient

(2015) Manuela Rosa et al.   MOVEMENT DISORDERS

The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias

(2015) Antonio Cerasa et al.   MOVEMENT DISORDERS

The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study

(2015) Ruben Smith et al.   NEUROBIOLOGY OF AGING

Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia

(2015) Sean Austin O. Lim et al.   NEUROBIOLOGY OF DISEASE

Putaminal serotonergic innervation

(2015) Jee-Young Lee et al.   NEUROLOGY

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

(2015) Weixing Shen et al.   NEURON

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients

(2015) Manuela Mellone et al.   Frontiers in Cellular Neuroscience

The acute brain response to levodopa heralds dyskinesias in Parkinson disease

(2014) Damian M. Herz et al.   ANNALS OF NEUROLOGY

A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias

(2014) Antonio Cerasa et al.   BRAIN

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

(2014) R. Cilia et al.   BRAIN

Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism

(2014) Salvador Sierra et al.   Brain Structure & Function

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

(2014) PD MED Collaborative Group   LANCET

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

(2014) Erwan Bezard et al.   MOVEMENT DISORDERS

Direct and indirect pathways of basal ganglia: a critical reappraisal

(2014) Paolo Calabresi et al.   NATURE NEUROSCIENCE

Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia

(2014) I.A. Prescott et al.   NEUROBIOLOGY OF DISEASE

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models

(2014) Sherri L. Thiele et al.   NEUROBIOLOGY OF DISEASE

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia

(2014) Tim Fieblinger et al.   Nature Communications

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum

(2014) Gregory Porras et al.   Scientific Reports

Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease

(2013) Francisco Grandas   Expert Review of Neurotherapeutics

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

(2013) C Warren Olanow et al.   LANCET NEUROLOGY

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

(2013) C. Warren Olanow et al.   MOVEMENT DISORDERS

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease

(2012) A. Kishore et al.   BRAIN

Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation

(2012) Alfonso Fasano et al.   LANCET NEUROLOGY

Prefrontal thickening in PD with levodopa-induced dyskinesias: New evidence from cortical thickness measurement

(2012) Antonio Cerasa et al.   PARKINSONISM & RELATED DISORDERS

Abnormal bidirectional plasticity-like effects in Parkinson's disease

(2011) Y.-Z. Huang et al.   BRAIN

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation

(2011) A. E. Elia et al.   EUROPEAN JOURNAL OF NEUROLOGY

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease

(2011) Lonneke M.L. de Lau et al.   MOVEMENT DISORDERS

Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease

(2011) Aristide Merola et al.   MOVEMENT DISORDERS

Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task

(2011) Antonio Cerasa et al.   MOVEMENT DISORDERS

“Silly Walks” in Parkinson's disease: Unusual presentation of dopaminergic-induced dyskinesias

(2011) Evžen Růžička et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

(2011) Koen Van Laere et al.   NEUROBIOLOGY OF AGING

Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats

(2011) Christopher J. Barnum et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Patient perception of dyskinesia in Parkinson's disease

(2010) S. W. Hung et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease

(2010) P. Stathis et al.   MOVEMENT DISORDERS

Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease

(2010) Jee-Young Lee et al.   MOVEMENT DISORDERS

Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies

(2010) Alberto J. Espay   NEUROLOGIC CLINICS

Dyskinesia and the antiparkinsonian response always temporally coincide: A retrospective study

(2010) J. G. Nutt et al.   NEUROLOGY

l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

(2008) Emanuela Santini et al.   JOURNAL OF NEUROCHEMISTRY

Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization

(2008) C. Fiorentini et al.   MOLECULAR PHARMACOLOGY

Placebo influences on dyskinesia in Parkinson's disease

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD

(2008) R. Katzenschlager et al.   NEUROLOGY

Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?

(2008) Agnès Nadjar et al.   PROGRESS IN NEUROBIOLOGY